Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2113809 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL1856467 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL2113807 | 1.00 | — | — | |
| SCHEMBL50585 | 0.97 | — | — | |
| SCHEMBL4012275 | 0.97 | — | — | |
| SCHEMBL50584 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL1066405 | 0.85 | — | — | |
| Hydrochloric Acid SCHEMBL2113214 | 0.85 | — | — | |
| Hydrochloric Acid SCHEMBL3224238 | 0.85 | — | — | |
| Hydrochloric Acid SCHEMBL6067784 | 0.85 | L3MBTL1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12533354-B2 | Triaryl compounds for treatment of PD-L1 diseases | CHEMOCENTRYX, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20230044941-A1 | TRIARYL COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX, INC. | 2023-02-09 | — | — | US | disclosed |
| CN-114340633-A | Triaryl compounds for the treatment of PD-L1 disease | 凯莫森特里克斯股份有限公司 | 2022-04-12 | — | — | CN | disclosed |
| EP-3968996-A1 | TRIARYL COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES | ChemoCentryx, Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
| US-11266643-B2 | Triaryl compounds for treatment of PD-L1 diseases | CHEMOCENTRYX, INC. (US) | 2022-03-08 | — | — | US | disclosed |
| US-20200383979-A1 | TRIARYL COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX, INC. | 2020-12-10 | — | — | US | disclosed |
| US-9255111-B2 | Parasiticidal dihydroisoxazole compounds | ELI LILLY AND COMPANY (US) | 2016-02-09 | — | — | US | disclosed |
| EP-2918583-A1 | PARASITICIDAL DIHYDROISOXAZOLE COMPOUNDS | ELI LILLY AND CO. (US) | 2015-09-16 | — | — | EP | disclosed |
| EP-2710000-B1 | PARASITICIDAL DIHYDROISOXAZOLE COMPOUNDS | LILLY CO ELI (US) | 2015-04-29 | — | — | EP | disclosed |
| US-20150072993-A1 | Parasiticidal Dihydroisoxazole Compounds | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2015-03-12 | — | — | US | disclosed |
| US-8889710-B2 | Parasiticidal dihydroisoxazole compounds | ELI LILLY AND COMPANY (US) | 2014-11-18 | — | — | US | disclosed |
| US-20140107149-A1 | PARASITICIDAL DIHYDROISOXAZOLE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2014-04-17 | — | — | US | disclosed |
| US-8648081-B2 | Parasiticidal dihydroisoxazole compounds | ELI LILLY AND COMPANY (US) | 2014-02-11 | — | — | US | disclosed |
| US-20130217699-A1 | PARASITICIDAL DIHYDROISOXAZOLE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2013-08-22 | — | — | US | disclosed |
| WO-2012155352-A1 | DIHYDROISOXAZOLE COMPOUNDS, PARASITICIDAL USES AND FORMULATIONS THEREOF | ELI LILLY AND COMPANY (US) | 2012-11-22 | — | — | WO | disclosed |
| US-8158638-B2 | Pyrazolopyrimidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-04-17 | — | — | US | disclosed |
| EP-2065388-B1 | PYRAZOLOPYRIMIDINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2011-09-07 | — | — | EP | disclosed |
| US-20100113410-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-05-06 | — | — | US | disclosed |
| EP-2065388-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2009-06-03 | — | — | EP | disclosed |